SOURCE: Mazal Plant Pharmaceuticals Inc.

June 12, 2008 10:54 ET

Mazal Plant Pharmaceuticals Announces Filing of Provisional Patent for Cholesterol/HDL Investigational New Drug Formulation

NEW YORK, NY--(Marketwire - June 12, 2008) - Mazal Plant Pharmaceuticals Inc. (PINKSHEETS: MZPP) (FRANKFURT: M9J) announced the filing of a provisional patent for its Cholesterol/HDL Investigatonal New Drug formulation. Mazal has already been issued a patent covering its original, first generation formula.

Eliyahu Tolchinsky, Mazal's CEO, said, "Building the company's intellectual portfolio is an important part of building Mazal Plant Pharmaceuticals Inc. in tandem with pending clinical trials."

About Mazal Plant Pharmaceuticals, Inc.

Mazal Plant Pharmaceuticals, Inc. is an early-stage whole plant pharmaceutical development company whose mission is to develop treatments for chronic diseases from combinations of whole plants and to build shareholder value through negotiated relationships with strategic partners to fund commercialization and marketing of these treatments on a stand-alone or combination basis.

Mazal Plant Pharmaceuticals has been approved to conduct a large-scale, double-blind, 4-arm study in human subjects diagnosed with alphalipoproteinemia (subjects with low HDL). The subjects will be given either MAHDL, placebo, Statin + Placebo or MAHDL + Statin for 4 months and tested for changes in HDL, LDL, Cholesterol, Triglycerides and CRP serum levels.

Additional information on Mazal Plant Pharmaceuticals, Inc. may be found at:

Forward-Looking Statements

"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Mazal Plant Pharmaceuticals Inc., to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Mazal Plant Pharmaceuticals Inc.'s subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Mazal Plant Pharmaceuticals assumes no responsibility to update the information included herein for events occurring after the date hereof.

Contact Information

  • Contact:

    LC Group
    Rick Lutz
    (404) 261-1196